Plague vaccine: recent progress and prospects
- PMID: 30792905
- PMCID: PMC6379378
- DOI: 10.1038/s41541-019-0105-9
Plague vaccine: recent progress and prospects
Abstract
Three great plague pandemics, resulting in nearly 200 million deaths in human history and usage as a biowarfare agent, have made Yersinia pestis as one of the most virulent human pathogens. In late 2017, a large plague outbreak raged in Madagascar attracted extensive attention and caused regional panics. The evolution of local outbreaks into a pandemic is a concern of the Centers for Disease Control and Prevention (CDC) in plague endemic regions. Until now, no licensed plague vaccine is available. Prophylactic vaccination counteracting this disease is certainly a primary choice for its long-term prevention. In this review, we summarize the latest advances in research and development of plague vaccines.
Conflict of interest statement
The authors declare no competing interests.
References
-
- CDC: 4 deaths, 15 cases of bubonic plague in U.S. this year. http://cbs4indy.com/2015/10/22/cdc-4-deaths-15-cases-of-bubonic-plague-i....
-
- WHO. Plague—Madagascar. http://www.who.int/csr/don/15-november-2017-plague-madagascar/en/ (2017).
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
